Despite marked tumor shrinkage after 5-FU treatment, the frequency of colon cancer relapse indicates that a fraction of tumor cells survives treatment causing tumor recurrence. The majority of cancer cells divert metabolites into anabolic pathways through Warburg behavior giving an advantage in terms of tumor growth. Here, we report that treatment of colon cancer cell with 5-FU selects for cells with mesenchymal stem-like properties that undergo a metabolic reprogramming resulting in addiction to OXPHOS to meet energy demands. 5-FU treatment-resistant cells show a de novo expression of pyruvate kinase M1 (PKM1) and repression of PKM2, correlating with repression of the pentose phosphate pathway, decrease in NADPH level and in antioxidant de...
Chemotherapy treatment of metastatic colon cancer ultimately fails due to development of drug resist...
Cancer cells adapt cellular metabolism to cope with their high proliferation rate. Instead of primar...
5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)....
Despite marked tumor shrinkage after 5-FU treatment, the frequency of colon cancer relapse indicates...
Recent studies have shown that oxidative phosphorylation (OXPHOS) is a target for the effective atte...
The ability to selectively eradicate oncogene-addicted tumors while reducing systemic toxicity has e...
Tumor cells exhibit metabolic reprogramming according to microenvironmental scenarios (i.e. stroma ...
Metabolic rearrangements are essential to satisfy the different needs of cancer cells during tumorig...
PURPOSE: Chemotherapy treatment of metastatic colon cancer ultimately fails due to development of dr...
Colorectal cancer is the second most common cancer in women, the third in men, and an important caus...
[eng] Colorrectal cancer (CRC) develops following a hierarchical model of heterogeneous cell populat...
The importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and i...
There is an emerging body of evidence that chemoresistance and minimal residual disease result from ...
We investigated the metabolic profile of cancer stem cells (CSC) isolated from patients with epithel...
Drug resistance of cancer cells is recognized as the primary cause of failure of chemotherapeutic tr...
Chemotherapy treatment of metastatic colon cancer ultimately fails due to development of drug resist...
Cancer cells adapt cellular metabolism to cope with their high proliferation rate. Instead of primar...
5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)....
Despite marked tumor shrinkage after 5-FU treatment, the frequency of colon cancer relapse indicates...
Recent studies have shown that oxidative phosphorylation (OXPHOS) is a target for the effective atte...
The ability to selectively eradicate oncogene-addicted tumors while reducing systemic toxicity has e...
Tumor cells exhibit metabolic reprogramming according to microenvironmental scenarios (i.e. stroma ...
Metabolic rearrangements are essential to satisfy the different needs of cancer cells during tumorig...
PURPOSE: Chemotherapy treatment of metastatic colon cancer ultimately fails due to development of dr...
Colorectal cancer is the second most common cancer in women, the third in men, and an important caus...
[eng] Colorrectal cancer (CRC) develops following a hierarchical model of heterogeneous cell populat...
The importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and i...
There is an emerging body of evidence that chemoresistance and minimal residual disease result from ...
We investigated the metabolic profile of cancer stem cells (CSC) isolated from patients with epithel...
Drug resistance of cancer cells is recognized as the primary cause of failure of chemotherapeutic tr...
Chemotherapy treatment of metastatic colon cancer ultimately fails due to development of drug resist...
Cancer cells adapt cellular metabolism to cope with their high proliferation rate. Instead of primar...
5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)....